Catecholaminergic polymorphic ventricular tachycardia 2 is a rare genetic heart rhythm disorder that triggers dangerous fast heartbeats during stress or exercise. People with CPVT2 often have fainting, dizziness, or sudden palpitations with activity or strong emotions, and some have no symptoms at rest. It usually begins in childhood or adolescence and continues lifelong, though severity can vary. The main treatments are beta blockers and often flecainide, and many also need an implantable defibrillator or activity guidance. The condition can be life‑threatening without treatment, but with early diagnosis and ongoing care many people live full lives.
Overview
Catecholaminergic polymorphic ventricular tachycardia 2Symptoms
Catecholaminergic polymorphic ventricular tachycardia 2 often first recognized in childhood; features include fainting, pounding or racing heartbeat, and dizziness during exercise or strong emotions. Some have brief seizures or collapse. At rest, many feel well until a trigger occurs.
Outlook and prognosis
Many people with catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2) do well long term with the right plan—trigger awareness, medicines like beta blockers, and sports/activity guidance. Early diagnosis and family screening lower risk. Implantable defibrillators are considered selectively.
Causes and risk factors
Catecholaminergic polymorphic ventricular tachycardia 2 arises from inherited CASQ2 gene changes, usually autosomal recessive. Risk rises with family history; intense exercise, strong emotions, stimulants (caffeine, decongestants), and electrolyte imbalances can trigger dangerous rhythms.
Genetic influences
Genetics are central in Catecholaminergic polymorphic ventricular tachycardia 2, most often caused by RYR2 variants. These changes affect calcium handling in heart cells, triggering dangerous rhythm surges during stress or exercise. Inherited in an autosomal dominant pattern, family screening is crucial.
Diagnosis
Doctors suspect CPVT2 when exercise or stress triggers fainting and characteristic arrhythmias on exercise ECG or Holter monitoring. Genetic diagnosis of Catecholaminergic polymorphic ventricular tachycardia 2 is confirmed with CASQ2 testing; relatives are often screened.
Treatment and drugs
Treatment for catecholaminergic polymorphic ventricular tachycardia 2 focuses on preventing dangerous rhythm surges, especially during exercise or stress. Care typically includes daily beta blockers, often with flecainide, plus activity guidance and emergency planning. Some may benefit from left cardiac sympathetic denervation or an implantable defibrillator.
Symptoms
People living with catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2) often feel well at rest, but exercise or strong emotions can bring on heart rhythm problems. Features vary from person to person and can change over time. Early features of catecholaminergic polymorphic ventricular tachycardia 2 often include fainting during sports, a racing heartbeat, or seizure‑like spells triggered by stress. Many first notice these patterns in childhood or the teen years.
Passing out during running, swimming, or intense play is common in CPVT2. It is triggered by a surge of stress hormones that can set off a dangerous heart rhythm. Episodes can happen within minutes of starting activity or during cool‑down.
Surprises, arguments, or fear can bring on the same heart rhythm problem. People may feel sudden weakness, gray vision, or collapse. Calming down usually helps, but the risk of a serious rhythm remains.
Some feel pounding or fluttering in the chest during exertion or stress. The rhythm can become very fast and irregular in CPVT2. Palpitations may be brief or build into fainting.
Lightheadedness, tunnel vision, or near‑fainting can occur with activity. Sitting or lying down may ease it. These warning signs often appear seconds before a blackout.
How people usually first notice Catecholaminergic polymorphic ventricular tachycardia 2?
People often first notice catecholaminergic polymorphic ventricular tachycardia 2 during childhood or the teen years when sudden pounding heartbeats, fainting, or seizures happen with exercise, strong emotions, or startle; these episodes usually stop at rest, so they can be easy to dismiss at first. Families may recall near-fainting during sports, unexplained collapses in swimming or running, or a scary “seizure” that doctors later trace to a heart rhythm problem rather than the brain — these are common first signs of CPVT2. In some cases, the first clue is a relative with exercise-triggered fainting or a sudden cardiac arrest, prompting doctors to look more closely at how CPVT2 is first noticed in others in the family.
Types of Catecholaminergic polymorphic ventricular tachycardia 2
Catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2) has recognized genetic variants that influence age at first symptoms, how easily episodes are triggered, and long‑term risk. CPVT is usually triggered by physical activity or strong emotions, leading to fainting or sudden palpitations during exercise or stress. Not everyone will experience every type. Clinicians often describe them in these categories:
Biallelic CPVT2
Both copies of the CASQ2 gene carry disease‑causing changes. Symptoms often start earlier in childhood and can be more frequent during exertion. People may have higher risk of severe episodes without treatment.
Monoallelic CPVT2
One copy of the CASQ2 gene carries a disease‑causing change. Symptoms may appear later and can range from none to exertion‑triggered palpitations or fainting. Risk varies by the specific change and family history.
Compound heterozygous
Two different harmful changes affect the CASQ2 gene, one on each copy. This usually behaves like biallelic CPVT2, with early, stress‑triggered events. Episodes can cluster during sports or intense emotions.
Founder variants
Certain communities share the same CASQ2 change passed down over generations. Severity can be similar within families, but still varies person to person. Knowing the specific variant can guide family testing and counseling.
Genotype‑negative relatives
Family members without the CASQ2 variant generally are not considered to have CPVT2. They may still undergo evaluation if symptoms arise or if testing was inconclusive. This helps clarify who needs ongoing monitoring for types of CPVT2 concerns.
What genetics can tell you about symptoms
In CPVT2, disease-causing variants in the CASQ2 gene disrupt calcium storage in heart muscle, triggering dangerous fast rhythms during exercise or strong emotion. People may feel pounding heartbeats, dizziness, fainting, or seizures, and some experience sudden cardiac arrest without warning.
Causes and risk factors
Catecholaminergic polymorphic ventricular tachycardia 2 is usually caused by changes in the CASQ2 gene that disturb calcium control in heart cells during stress.
Most people inherit two changed copies, one from each parent, though a new change can also happen.
Having a gene change doesn’t mean you’ll definitely develop the condition.
Episodes are often triggered by exercise, strong emotions, or stimulants like caffeine or some decongestants.
Key risk factors for catecholaminergic polymorphic ventricular tachycardia 2 include fainting during exertion or sudden death in the family, and risk can be lower when people avoid high-intensity sports and stimulant drugs.
Environmental and biological risk factors
Day-to-day surges in stress hormones are the main external drivers of when this heart rhythm problem shows itself. In many people, early symptoms of catecholaminergic polymorphic ventricular tachycardia 2 appear during exercise or strong emotions. Genes provide a baseline, but daily surroundings add new layers. Below are biological and environmental factors that can raise the chance of an episode.
Rapid increases in heart rate release adrenaline. This surge can trigger abnormal rhythms in catecholaminergic polymorphic ventricular tachycardia 2.
Strong emotions quickly activate the stress response. The abrupt adrenaline spike can set off an episode.
Drugs such as epinephrine, isoproterenol, or certain decongestants stimulate the fight-or-flight system. Exposure can raise the chance of an event in catecholaminergic polymorphic ventricular tachycardia 2.
Cocaine, amphetamines, and some energy products boost adrenaline. These exposures can lower the threshold for dangerous rhythms.
Genetic risk factors
Catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2) stems from inherited changes that alter how heart cells handle calcium, most often in the CASQ2 gene. Doctors identify genetic risk factors for Catecholaminergic polymorphic ventricular tachycardia 2 mainly through changes in CASQ2 and how those changes are inherited. Carrying a genetic change doesn’t guarantee the condition will appear, but certain patterns can raise the chance of dangerous heart rhythms.
CASQ2 gene changes: Pathogenic changes in the CASQ2 (calsequestrin-2) gene disrupt how heart muscle cells store and release calcium. This disrupted signaling can set the stage for the abnormal rhythms seen in CPVT2. Genetic testing can identify these specific changes.
Autosomal recessive pattern: The highest risk occurs when two faulty CASQ2 copies are inherited—one from each parent. Parents with one faulty copy are usually healthy carriers. With two carriers, each pregnancy has a 25% chance of an affected child.
Single-copy carriers: People with one altered CASQ2 copy usually do not develop Catecholaminergic polymorphic ventricular tachycardia 2. Some carriers may have no symptoms and normal testing throughout life. Doctors may still advise family-based screening to clarify risk.
Two different changes: Some people inherit two different CASQ2 changes (one from each parent), while others inherit the same change from both parents. Either situation can lead to Catecholaminergic polymorphic ventricular tachycardia 2. The specific combination can influence how early rhythm problems first appear.
Variant effect strength: Changes that severely reduce or eliminate CASQ2 protein may carry higher risk than milder changes that only alter its function. Lab classifications help indicate how strong the evidence is. Your genetics team can translate these labels into personal risk.
Family history clues: Having a relative with a known CASQ2 pathogenic change increases the chance that others in the family carry it. Targeted cascade genetic testing can pinpoint who is at genetic risk for Catecholaminergic polymorphic ventricular tachycardia 2. This can guide who needs cardiac evaluation.
Related parents: When parents are closely related, they are more likely to share the same rare CASQ2 change. This raises the chance a child inherits two faulty copies and develops CPVT2. Genetic counseling can explain specific family risks.
Variable expression: People with the same CASQ2 changes can have different severity and age when symptoms begin. Risk is not destiny—it varies widely between individuals. Doctors consider genetic results alongside family patterns and clinical findings.
Lifestyle risk factors
Everyday habits do not cause CPVT2, but they can trigger adrenergic surges that set off dangerous heart rhythms. Adjusting routines can lower arrhythmia risk and complement medical therapy. This overview focuses on lifestyle risk factors for Catecholaminergic polymorphic ventricular tachycardia 2.
High-intensity exertion raises catecholamines and can provoke ventricular arrhythmias in CPVT2. Limiting to low-intensity activity as advised by your cardiology team can reduce events.
Sustained competition and sudden bursts of effort increase adrenergic load and trigger polymorphic VT. Avoiding competitive settings helps prevent dangerous rhythm episodes.
Cold water entry and exertion while swimming can cause abrupt catecholamine surges. Choosing gentle, supervised activities on land may be safer.
Strong emotions, anxiety, or startle responses can precipitate arrhythmias through sympathetic activation. Stress-reduction skills and calm routines can lower episode frequency.
Risk prevention
You can’t change the genes that cause Catecholaminergic polymorphic ventricular tachycardia 2, but you can lower the chance of dangerous heart rhythm episodes. Most prevention focuses on avoiding triggers, taking medicines as prescribed, and staying connected with heart specialists. Prevention is about lowering risk, not eliminating it completely. Plans are tailored by age, symptoms, and activity level, and they often evolve over time.
Take beta‑blockers exactly as prescribed, and ask whether flecainide is appropriate for you. Skipping doses can raise the risk of an arrhythmia during stress or exercise.
Avoid high‑intensity or competitive sports that spike adrenaline. A cardiologist can set a safe, individualized activity plan so you can stay active without pushing into risky zones.
Strong emotions can trigger episodes, so build routines for calm such as paced breathing or guided relaxation. Some may benefit from counseling or biofeedback to manage adrenaline surges.
Steer clear of energy drinks, excess caffeine, and over‑the‑counter decongestants with stimulants. Always check labels and ask your doctor or pharmacist before new medications.
Transmission
Catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2) is not contagious—you can’t catch it or pass it by touch, coughing, or blood. CPVT2 is inherited in an autosomal recessive way, meaning it usually appears when both parents carry one nonworking copy of the same gene but do not have symptoms themselves. When two carriers have a child, each pregnancy has a 25% chance the child will have CPVT2, a 50% chance the child will be a carrier, and a 25% chance the child will inherit neither copy. Someone living with CPVT2 will pass one nonworking copy to all children; if the other parent is not a carrier the children are carriers only, but if the other parent is a carrier there is a 50% chance for an affected child in each pregnancy. Genetic counseling and testing can help families understand how Catecholaminergic polymorphic ventricular tachycardia 2 is inherited and clarify risks for relatives.
When to test your genes
Test your genes if you faint during exercise or strong emotion, have unexplained seizures or “near-drowning” episodes, or a family history of sudden cardiac death, fainting, or CPVT. Genetic testing helps confirm CPVT2, guides medication choices like beta‑blockers, and flags relatives who may also be at risk. Early diagnosis enables activity planning and emergency preparedness.
Diagnosis
People with Catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2) are often flagged for testing after fainting, near-fainting, or sudden palpitations during exercise, strong emotions, or fever. Because the resting heartbeat can look normal, the diagnosis focuses on finding rhythm changes when the heart is under stress and ruling out structural heart disease. Early and accurate diagnosis can help you plan ahead with confidence. In many cases, the genetic diagnosis of Catecholaminergic polymorphic ventricular tachycardia 2 confirms the cause and guides care for you and your family.
Your provider asks about fainting, chest fluttering, or seizures that happen with exercise, excitement, or stress. Details about when and how episodes start can point toward CPVT2.
Relatives with stress‑related fainting, seizures, or sudden cardiac arrest may raise suspicion. Family history is often a key part of the diagnostic conversation.
A standard electrocardiogram checks your heart’s rhythm at rest. CPVT2 often shows a normal pattern when you’re not stressed, so a normal result does not rule it out.
Walking or running on a treadmill while monitored can reveal the characteristic irregular rhythms of CPVT2. Doctors look for abnormal beats that appear as the heart rate rises.
Stages of Catecholaminergic polymorphic ventricular tachycardia 2
Catecholaminergic polymorphic ventricular tachycardia 2 does not have defined progression stages. It tends to trigger sudden rhythm episodes during exercise or strong emotions rather than a steady, step-by-step decline; early symptoms of Catecholaminergic polymorphic ventricular tachycardia 2 can include pounding heartbeats, lightheadedness, or fainting with activity. Different tests may be suggested to help confirm the diagnosis, such as an exercise stress test and wearable heart rhythm monitoring over 24–48 hours. Your care team will also review your personal and family history, and may use genetic testing to pinpoint the cause and guide treatment decisions.
Outlook and prognosis
Living with Catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2) often means planning around adrenaline surges—rushing to catch a train, a tough workout, or a scare can trigger a racing, dangerous rhythm. Many people ask, “What does this mean for my future?”, and the honest answer is that risk varies with age, triggers, and how consistently treatment is used. With ongoing care, many people maintain good day‑to‑day health and remain active, sometimes with adjustments like exercising with a buddy, using a heart‑rate monitor, or choosing lower‑intensity activities.
Prognosis refers to how a condition tends to change or stabilize over time. For CPVT2, medicines that blunt adrenaline effects are the backbone of care and lower the chance of fainting or cardiac arrest, and adding flecainide or a left cardiac sympathetic denervation procedure can further reduce episodes when needed. An implantable cardioverter‑defibrillator (ICD) may be used for people with prior life‑threatening events or persistent arrhythmias despite medication, but it’s usually paired with medicines to prevent shocks from exercise‑induced rhythms. The highest untreated risk is in childhood and adolescence; with modern therapy and trigger awareness, the long‑term outlook has improved substantially. Early symptoms of CPVT2—like fainting during intense exercise or strong emotions—should prompt specialist evaluation, since early care can make a real difference.
Everyone’s journey looks a little different. Some people never experience another event once on treatment and avoiding key triggers, while others have occasional breakthroughs, often when doses are missed or stress is high. Sudden death can occur if CPVT2 is unrecognized or undertreated, but when therapy is followed closely and family members at risk are screened, mortality drops markedly. Genetic testing can sometimes provide more insight into prognosis, and close relatives may benefit from screening even if they feel well. Talk with your doctor about what your personal outlook might look like, including safe activity plans, travel and school or work accommodations, and how to respond if warning signs return.
Long-term effects
Catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2) is a lifelong, stress-triggered heart rhythm disorder. Over time, it can lead to repeated fainting, injury risk, and in rare cases sudden cardiac arrest, especially during exercise or strong emotions. Long-term effects vary widely, and many people remain well between episodes. Some people notice in hindsight that the early symptoms of Catecholaminergic polymorphic ventricular tachycardia 2 began in childhood with unexplained fainting during sports.
Brief, sudden fainting (syncope) can recur with exercise or emotional stress. Many with CPVT2 feel well between episodes. Injuries may happen when falls occur.
Dangerous fast rhythms can rarely lead to cardiac arrest. The risk tends to be highest when adrenaline surges, like during intense activity or fright.
Loss of consciousness can cause head hits or fractures. Over years, some accumulate injuries tied to unexpected episodes.
Worry about episodes may lead to avoiding sports or strenuous play. This can affect school, work, and social life.
How is it to live with Catecholaminergic polymorphic ventricular tachycardia 2?
Living with catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2) often means planning your day around heart safety—keeping intense exercise, startling situations, and strong emotional spikes in check, and taking medicines exactly as prescribed. Many find reassurance in having an action plan, wearing a medical ID, and letting coaches, teachers, and coworkers know what to do if symptoms like fainting or sudden palpitations appear. Family members may feel anxious at first, but with clear guidance on emergency steps, CPR training, and shared routines for safe activity, most households settle into a steady rhythm. Over time, people with CPVT2 often become experts at reading their bodies, choosing activities that fit, and living fully with sensible guardrails.
Treatment and drugs
Catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2) is treated with medicines that steady the heart’s rhythm and with strategies that limit adrenaline surges that can trigger dangerous beats. First-line care usually includes a beta blocker taken every day; many also add flecainide to further reduce stress‑triggered arrhythmias. For people who still have episodes, doctors may recommend a left cardiac sympathetic denervation procedure, and in select high‑risk cases an implantable cardioverter-defibrillator (ICD) is considered as a safety net. Alongside medical treatment, lifestyle choices play a role, such as avoiding intense exertion, managing emotional stress, and using supervised, tailored exercise plans. Ask your doctor about the best starting point for you, and make a plan for emergency care and for screening close relatives.
Non-drug treatment
Daily life with catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2) often means managing triggers like sudden exertion or strong emotions that can set off dangerous heart rhythms. Alongside medicines, non-drug therapies can lower risk, support safety planning, and help you stay active within safe limits. These steps also help families spot early symptoms of catecholaminergic polymorphic ventricular tachycardia 2—like fainting during exercise—and know what to do fast. Plans are tailored by age, sport or job demands, and your individual risk.
Limit high-intensity bursts, competitive sports, and sudden sprints that rapidly raise adrenaline. Choose steady, light-to-moderate activity approved by your cardiology team. Reassess limits after any fainting or rhythm event.
Skip caffeine, energy drinks, and decongestants that can raise heart rate. Avoid recreational stimulants and discuss any supplements with your clinician. Check medication labels carefully.
Techniques like breathing exercises and biofeedback can blunt adrenaline surges. Short, regular practice helps reduce spikes during school, work, or sports. Non-drug options can be practical day to day.
An implantable cardioverter-defibrillator can treat life-threatening rhythms if they occur. It is considered for people with CPVT2 at higher risk or with prior serious events. Decisions weigh benefits against shocks and device care.
Your genes may have an impact on how drugs work for you
Medicines for catecholaminergic polymorphic ventricular tachycardia 2 can work differently depending on your genes, which affect heart cell channels and how your body processes drugs. Genetic results may guide choices and doses of beta‑blockers, flecainide, or device-based strategies.
Pharmacological treatments
Living with sudden, exercise‑triggered heart rhythm surges can make everyday activities feel uncertain. Medicines aim to calm the heart’s response to stress hormones and lower the risk of dangerous rhythms in Catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2). First-line medications are those doctors usually try first, based on how well they work and their safety. In many cases, first-line medications for CPVT2 are beta‑blockers, with other drugs added if symptoms or exercise‑induced arrhythmias continue.
Nadolol or propranolol are usually started first to blunt adrenaline’s effects and prevent stress‑ or exercise‑induced rhythms in CPVT2. Nadolol is often preferred for steady, all‑day coverage, while propranolol is another well‑studied option. Dose is tailored to heart rate, symptoms, and side effects like tiredness or cold hands.
Flecainide may be added when beta‑blockers alone don’t fully control CPVT2 arrhythmias. It helps suppress extra beats and dangerous rhythm bursts during exertion. Regular ECG checks and dose adjustments help balance benefit and safety.
Verapamil, a calcium‑channel blocker, can be considered if symptoms persist despite beta‑blockers, though its benefit is usually modest. It may be used short‑term or as an add‑on in selected cases. Blood pressure and constipation are the most common issues to watch.
In emergency settings, intravenous beta‑blockers like esmolol can quickly calm an adrenergic surge. Intravenous flecainide may be used in experienced centers if dangerous rhythms continue. These hospital‑based treatments stabilize rhythms while long‑term medications are optimized.
Genetic influences
Genetic changes play a central role in catecholaminergic polymorphic ventricular tachycardia 2, most often involving a heart muscle gene called CASQ2 that helps heart cells handle calcium. This subtype is usually inherited in an autosomal recessive pattern, meaning two gene changes—one from each parent—are typically needed to cause the condition. A “carrier” means you hold the gene change but may not show symptoms. When both parents are carriers, each pregnancy has about a 25% chance of a child with catecholaminergic polymorphic ventricular tachycardia 2, a 50% chance the child will be a carrier, and a 25% chance of neither. These gene changes disrupt calcium control inside heart cells during physical activity or stress, which can set off the dangerous heart rhythms seen in catecholaminergic polymorphic ventricular tachycardia 2. Genetic testing for catecholaminergic polymorphic ventricular tachycardia 2 can confirm the cause in someone affected and guide testing and counseling for relatives.
Is Catecholaminergic polymorphic ventricular tachycardia 2 genetic?
Genetics are central in Catecholaminergic polymorphic ventricular tachycardia 2, most often caused by RYR2 variants. These changes affect calcium handling in heart cells, triggering dangerous rhythm surges during stress or exercise. Inherited in an autosomal dominant pattern, family screening is crucial.
Pharmacogenetics—how genetics influence drug effects
A confirmed genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia 2 helps guide treatment toward beta-blockers like nadolol and, when needed, add-on flecainide to better control adrenaline‑triggered heart rhythms. The specific gene change doesn’t usually point to a different drug than in other CPVT types, but it supports starting these medicines early, carefully adjusting the dose, and avoiding stimulants that can raise heart rate. Beyond the condition itself, differences in genes that affect drug breakdown can shape dosing and side effects—especially for flecainide and propranolol, which are processed by a common liver enzyme (CYP2D6)—while nadolol is much less affected by those pathways. A “slow metabolizer” may process medicine more slowly, which can raise drug levels and the chance of side effects, while others break it down very quickly and may get less benefit at standard doses. When pharmacogenetic testing shows a CYP2D6 result such as poor or ultra‑rapid metabolism, doctors may adjust flecainide or propranolol doses, prefer nadolol, or monitor drug levels and heart tracings (ECG) more closely. Medicines that interact with CYP2D6, kidney function, age, and exercise triggers also influence medication response in catecholaminergic polymorphic ventricular tachycardia 2, so treatment is paired with regular follow‑up to confirm both safety and benefit.
Interactions with other conditions
Stress-related conditions and illnesses that boost adrenaline—like anxiety, hyperthyroidism, fever, or severe dehydration—can trigger or worsen the fast heart rhythms seen in Catecholaminergic polymorphic ventricular tachycardia 2. Doctors call it a “comorbidity” when two conditions occur together, and treatments for asthma, ADHD, or nasal congestion that act like stimulants or contain decongestants can make CPVT2 harder to control by revving the heart’s stress signals. While CPVT2 usually occurs in an otherwise normal heart, having cardiomyopathy or recent myocarditis can add extra strain and may increase the risk of dangerous rhythms during exercise or illness. Rarely, CPVT2 can occur alongside other inherited rhythm problems, such as long QT syndrome, and some conditions share underlying mechanisms, which can affect medication choices and who in the family should be tested. Beta‑blockers, a key therapy for CPVT2, may aggravate asthma symptoms and can blunt warning signs of low blood sugar in people with diabetes, so coordinated care is important. Early symptoms of Catecholaminergic polymorphic ventricular tachycardia 2—like fainting with exertion or intense emotions—can look like panic attacks or seizures, which may delay finding the heart cause when those diagnoses are also present.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described sudden fainting spells in healthy children during play or sports, episodes that often followed a fright, a sprint, or a high fever. Families and communities once noticed patterns—more than one child affected, or relatives who collapsed in stressful moments—long before doctors could see what was happening inside the heart. For many, these events were rare but terrifying, and they sometimes ended without warning.
Early medical reports from the 20th century gathered these stories into case series of stress‑triggered collapses with normal heart structure on exam. Initially understood only through symptoms, later investigators captured fast, irregular heart rhythms during exercise testing, which pointed to the heart’s electrical system rather than blocked arteries or weak muscle. As portable monitors and treadmill tests became common, the distinctive pattern—harmless at rest, dangerous during sudden surges of adrenaline—came into focus.
From early theories to modern research, the story of Catecholaminergic polymorphic ventricular tachycardia 2 built step by step as genetic tools advanced. In the 1990s and early 2000s, teams linked these stress‑induced rhythms to genes that help calcium move in and out of heart cells, including a gene called CASQ2. This variant of the condition, often called CPVT2, showed that even a small change in how the heart stores calcium can act like a faulty dimmer switch, letting electrical signals flicker and race when emotions run high or during exercise.
Over time, descriptions became more precise. Doctors learned that people with CPVT2 often have normal checkups and a normal resting electrocardiogram, which explained why earlier generations struggled to find a cause. Exercise stress tests, heart rhythm monitors, and—when appropriate—genetic testing made the diagnosis clearer and allowed families to understand who else might be at risk. In recent decades, awareness has grown as sports screenings, emergency response training, and access to defibrillators have improved survival after sudden events.
These historical steps changed care. What began as scattered reports of unexplained collapses led to targeted treatments—beta‑blockers to blunt adrenaline surges, carefully guided exercise plans, and in some cases implantable devices or specialized medications. Knowing the condition’s history helps explain why a detailed family story and a monitored exercise test still sit at the center of evaluation today. It also shows why many living with Catecholaminergic polymorphic ventricular tachycardia 2 can lead full, active lives once the rhythm risk is recognized and managed.